D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$454M |
| 2 |
Apple
AAPL
|
+$364M |
| 3 |
Procter & Gamble
PG
|
+$314M |
| 4 |
Verizon
VZ
|
+$308M |
| 5 |
Pfizer
PFE
|
+$299M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$735M |
| 2 |
Emerson Electric
EMR
|
+$423M |
| 3 |
Biogen
BIIB
|
+$354M |
| 4 |
PayPal
PYPL
|
+$349M |
| 5 |
Amazon
AMZN
|
+$338M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.77% |
| 2 | Healthcare | 11.58% |
| 3 | Consumer Discretionary | 8.97% |
| 4 | Financials | 7.64% |
| 5 | Communication Services | 5.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RARX
2501
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.23M | ﹤0.01% |
+25,580
| New | +$1.19M |
|
2502
MSC Industrial Direct
MSM
$7.07B
| $1.23M | ﹤0.01% |
22,321
-48,901
| -69% | -$3.22M |
|
2503
CALL
W.P. Carey
WPC
$17B
| $1.23M | ﹤0.01% |
21,543
-11,742
| -35% | -$891K |
|
2504
PUT
Axsome Therapeutics
AXSM
$12.3B
| $1.22M | ﹤0.01% |
+20,800
| New | +$1.69M |
|
2505
Grupo Cibest SA
CIB
$20.9B
| $1.22M | ﹤0.01% |
49,046
+32,736
| +201% | +$1.47M |
|
2506
PUT
Avnet
AVT
$7.25B
| $1.22M | ﹤0.01% |
+48,700
| New | +$1.66M |
|
|
HAPN
2507
PUT
Happen Inc
HAPN
$2.16B
| $1.22M | ﹤0.01% |
155,700
+79,100
| +103% | +$881K |
|
2508
PUT
EQT Corp
EQT
$32.5B
| $1.22M | ﹤0.01% |
171,900
| – | – |
|
|
JWN
2509
PUT
DELISTED
Nordstrom
JWN
| $1.22M | ﹤0.01% |
79,200
-82,100
| -51% | -$2.74M |
|
2510
PUT
PagerDuty
PD
$753M
| $1.21M | ﹤0.01% |
+70,000
| New | +$1.49M |
|
2511
Helmerich & Payne
HP
$3.36B
| $1.21M | ﹤0.01% |
77,125
-460,281
| -86% | -$16.2M |
|
2512
PUT
Tapestry
TPR
$29.8B
| $1.21M | ﹤0.01% |
93,200
-4,800
| -5% | -$112K |
|
2513
CALL
Edgewell Personal Care
EPC
$1.28B
| $1.2M | ﹤0.01% |
+50,000
| New | +$1.49M |
|
2514
KRONOS Worldwide
KRO
$705M
| $1.2M | ﹤0.01% |
142,620
+61,169
| +75% | +$643K |
|
2515
Omnicell
OMCL
$1.89B
| $1.2M | ﹤0.01% |
+18,351
| New | +$1.46M |
|
2516
CALL
Iovance Biotherapeutics
IOVA
$2.19B
| $1.2M | ﹤0.01% |
+40,000
| New | +$1.06M |
|
2517
PUT
Signet Jewelers
SIG
$3.72B
| $1.2M | ﹤0.01% |
185,600
-124,000
| -40% | -$2.54M |
|
2518
CALL
Xerox
XRX
$357M
| $1.2M | ﹤0.01% |
63,200
| – | – |
|
|
KSU
2519
PUT
DELISTED
Kansas City Southern
KSU
| $1.2M | ﹤0.01% |
9,400
-200
| -2% | -$30.5K |
|
2520
MidCap Financial Investment
MFIC
$790M
| $1.19M | ﹤0.01% |
176,932
-118,694
| -40% | -$1.77M |
|
2521
TransDigm Group
TDG
$71.9B
| $1.19M | ﹤0.01% |
+3,730
| New | +$2.03M |
|
2522
Clean Harbors
CLH
$15.9B
| $1.19M | ﹤0.01% |
+23,223
| New | +$1.7M |
|
|
LKFT
2523
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
| $1.19M | ﹤0.01% |
6,073
+2,373
| +64% | +$511K |
|
2524
OceanFirst Financial
OCFC
$1.7B
| $1.19M | ﹤0.01% |
74,812
-34,266
| -31% | -$724K |
|
|
APLT
2525
DELISTED
Applied Therapeutics
APLT
| $1.19M | ﹤0.01% |
+36,338
| New | +$1.47M |
|
Similar funds
D.E. Shaw & Co's Q1 2020 Portfolio in Review
As of Q1 2020, D.E. Shaw & Co held 4,498 positions worth $64.1B, down 27% from $87.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
D.E. Shaw & Co withdrew a net $5.59B in Q1 2020, closing 626 positions and reducing 1,723 holdings. Its most notable exit was PG&E, an estimated $79M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, D.E. Shaw & Co opened a new position in iShares iBoxx $ Investment Grade Corporate Bond ETF worth $124M.
- D.E. Shaw & Co's largest Q1 2020 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 1,005,000 shares worth $124M.
- D.E. Shaw & Co added most to ExxonMobil in Q1 2020, an estimated $454M increase.
- D.E. Shaw & Co's biggest Q1 2020 reduction was Tesla, cutting an estimated $735M.
- D.E. Shaw & Co fully exited PG&E in Q1 2020, selling an estimated $79M.
- D.E. Shaw & Co's ten largest holdings make up 12% of its $64.1B portfolio in Q1 2020.
- D.E. Shaw & Co opened 538 new positions and closed 626 in Q1 2020.
- D.E. Shaw & Co's portfolio value fell 27% quarter-over-quarter to $64.1B.
Based on D.E. Shaw & Co's 13F filing for Q1 2020, filed 15 May 2020.